Teclistamab in Relapsed or Refractory Multiple Myeloma
Work
Year: 2022
Type: article
Abstract: Teclistamab is a T-cell–redirecting bispecific antibody that targets both CD3 expressed on the surface of T cells and B-cell maturation antigen expressed on the surface of myeloma cells. In the phase ... more
Source: New England Journal of Medicine
Authors Philippe Moreau, Alfred L. Garfall, Niels W.C.J. van de Donk, Hareth Nahi, Jesús F. San Miguel +29 more
Institutions Hotel Dieu Hospital, University of Pennsylvania, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Karolinska University Hospital +28 more
Cites: 25
Cited by: 629
Related to: 10
FWCI: 155.3
Citation percentile (by year/subfield): 99.99
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Sustainable Development Goal Good health and well-being
Open Access status: bronze